On the Rebound with Gilead Sciences

Nicholas Vardy

Nicholas Vardy has a unique background that has proven his knack for making money in different markets around the world.

It was a mostly flat week for the holiday-shortened week, as the Dow Jones rose 0.23%, the S&P 500 was up 0.22% and the NASDAQ eked out a 0.06% gain. Global markets fared much better with the MCSI Emerging Markets Index jumping 1.75%.

Big gainers in your Bull Market Alert portfolio included The Bank of Ireland (IRE) soaring 6.07%, Vipshop Holdings Limited (VIPS) gaining 4.51% and the iShares MSCI BRIC ETF (BKF) adding 2.53%.

Four positions hit new 52-week highs, including Flextronics International (FLEX)iShares MSCI BRIC ETF (BKF), United Rentals, Inc. (URI) and Trinity Industries (TRN).

This week’s Bull Market Alert recommendation is Gilead Sciences Inc. (GILD), a biotech giant well known for its success with HIV drugs and, lately, its hepatitis drug, Sovaldi.

Gilead endured an intraday pullback of as much as 8% on Friday before the stock rebounded, ending the day down 1.4%.

The panic ensued after Bloomberg reported the company is discussing selling a “cheaper version” of Sovaldi.

It turns out that Gilead is close to a deal with generic drug makers to bring cheaper versions of its $84,000 hepatitis C drug Sovaldi to approximately 80 developing nations, including India, Pakistan and Indonesia.

Under the terms of the deal set to close at the middle of this month, Gilead intends to sell Sovaldi directly in certain lower-income countries, including India, at $900 for 12 weeks of therapy. Sovaldi sells in the United States for a price of $1,000 a piece, or $84,000 for 12 weeks.

Less well informed investors sold the stock off sharply. In contrast, analysts who follow the company closely were left confused. After all, such a deal was already expected, and it is something Gilead already does with its HIV medication.

Exclusive  Putting the Panic in Perspective

In any case, from a pure earnings standpoint, any new sales will only add to Gilead’s profits, as almost all of its current profits are based in the few developed countries’ sales.

Trading at a forward price-to-earnings ratio (P/E) of 11.26, Gilead is now quite a cheap stock, considering both its sales and earnings are growing at a steep rate.

So buy Gilead Sciences Inc. (GILD) at market today and place your initial stop at $90.00.

If you want to play the options, I recommend the November $110 calls (GILD141122C00110000).

Portfolio Update 

The Bank of Ireland (IRE) soared 6.07% higher last week on positive news. The European Central Bank’s (ECB) surprise interest rate cut last week pushed many banks across Europe higher. A look at IRE’s chart also shows a rosy picture for future gains. IRE has been rocketing higher for the past several weeks after two months of trading sideways through July and August. IRE just punched up through the mighty 200-day moving average, signaling the possibility of a considerable future gain. IRE is a BUY.

Flextronics International (FLEX) closed the week flat. However, FLEX also benefited from positive news last week, even managing a new seven-year (and 52-week) high early in the week. FLEX received approval to repurchase up to 20% of its outstanding shares on Wednesday, causing a spike in share prices. The company can purchase shares in blocks of up to $500 million. This gives FLEX a significant tailwind for future gains. FLEX is a BUY.

iShares MSCI BRIC ETF (BKF) added 2.53% last week. BKF experienced spikes in both its price level and trading volume last week. BKF jumped to a new 52-week high early in the week as it spiked higher, following a pattern it has been experiencing since a mid-March low. However, last week’s jump occurred on significantly higher volume for this exchange-traded fund — the third-highest trade volume of the last one-year period. BKF is a BUY.

Exclusive  GLOBAL STOCK INVESTOR HOTLINE UPDATE 74

Trinity Industries (TRN) rose 0.23% last week and hit a new 52-week high. Analyst firm Stern Agee released a recommendation last week confirming my bullish outlook for this railcar maker. Despite already being up nearly 80% for 2014, Stern Agee issued a “Buy” on this stock, after forecasting a large capacity problem as a large positive for this manufacturer of railcars for many years to come. TRN is a BUY.

Nicholas Vardy

Like This Article?
Now Get Our FREE Special Report:
Alternative Investing: Investing in Timber

Stock Investor editor Paul Dykewicz reveals why investing in timber may be one of the best long-term portfolio strategies you'll find today.

Get Access to the Report, 100% FREE


img
previous article

Money: a simple word that, if you aren’t careful, can cause you a lot of problems. If not you, then maybe for a family member or a close friend.

PREMIUM SERVICES FOR INVESTORS

Dr. Mark Skousen

Named one of the "Top 20 Living Economists," Dr. Skousen is a professional economist, investment expert, university professor, and author of more than 25 books.

Product Details

LEARN MORE HERE

Bryan Perry

A former Wall Street financial advisor with three decades' experience, Bryan Perry focuses his efforts on high-yield income investing and quick-hitting options plays.

Product Details

LEARN MORE HERE

Jim Woods

Jim Woods has over 20 years of experience in the markets from working as a stockbroker,
financial journalist, and money manager. As well as a book author and regular contributor to
numerous investment websites, Jim is the editor of:

Product Details

LEARN MORE HERE

Bob Carlson

Bob Carlson provides independent, objective research covering all the financial issues of retirement and retirement planning. In addition, Bob serves as Chairman of the Board of Trustees of the Fairfax County (VA) Employees’ Retirement System, which has over $2.8 billion in assets.

Product Details

LEARN MORE HERE

Mike Turner

Mike Turner’s financial, mathematical, computer science and engineering background serves as the foundation for his disciplined, rules-based approach to trading. Mike’s three services include:

Product Details

LEARN MORE HERE

Hilary Kramer

Hilary Kramer is an investment analyst and portfolio manager with 30 years of experience on Wall Street. Since 2010, Hilary's financial publications have provided stock analysis and investment advice to her subscribers:

Product Details

LEARN MORE HERE

DividendInvestor.com

Used by financial advisors and individual investors all over the world, DividendInvestor.com is the premier provider and one-stop shop for dividend information and research.

Product Details

Popular tools include our proprietary Dividend Calendar, Dividend Calculator, Dividend Score Card, and many more.

LEARN MORE HERE